Use of sibutramine analogues to prevent the development of...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/135 (2006.01) A61K 31/137 (2006.01)

Patent

CA 2266401

A compound of formula (I) or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-{4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for reducing Insulin resistance in humans in whom Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus have not presented.

Cette invention porte sur un composé de la formule (I), ou un sel pharmaceutiquement acceptable dudit composé, dans laquelle R1 et R2 sont, indépendamment, H ou méthyle (par exemple, un chloryhdrate de N,N-diméthyl-1-[1-(4-chlorophényl)cyclobutyl]-3-méthylbutylamine, éventuellement sous la forme de son monohydrate). Ledit composé est utilisé pour diminuer la résistance insulinique chez les sujets chez qui l'intolérance au glucose et le diabète sucré non insulino-dépendant ne sont pas constatés.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of sibutramine analogues to prevent the development of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of sibutramine analogues to prevent the development of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of sibutramine analogues to prevent the development of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2016056

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.